ClinicalTrials.gg
CompletedNCT03499691Updated Mar 13, 2025

Exploratory Study to Explore the Safety and Efficacy of the HDx Therapy Using Theranova 500 Dialyzer in Comparison to Hemodiafiltration

An interventional study of Theranova 500 medium cut-off dialyzer and Hemodiafiltration in End Stage Renal Disease, sponsored by Vantive Health LLC. Completed at 1 site in Spain. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-03-13.

Sponsored by Vantive Health LLC (formerly part of Baxter Healthcare Corporation) · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 33 studies in Kidney Failure, Chronic by Baxter Healthcare Corporation — none open to participants now, none under way, none of them phase 3. Kidney Failure, Chronic · Baxter Healthcare Corporation.

Enrollment
15th of 29
43 · median 43
Started
2018
with 3 others
No phase
22 of 33
none open now
Registered
25th of 33
by date

Among the 33 studies in Kidney Failure, Chronic by Baxter Healthcare Corporation, this one is the 15th largest by enrollment of the 29 interventional ones that give a count, is one of 4 that started in 2018, is one of 22 with no phase, and was the 25th registered.

Kidney Failure, Chronic

2,114 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

None of the 33 studies in Kidney Failure, Chronic by Baxter Healthcare Corporation is open now. The open studies under Kidney Failure, Chronic, anywhere →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 33 studies in Kidney Failure, Chronic by Baxter Healthcare Corporation as a file.
02

Study summary

Today it is well established that middle molecules comprise several compounds that are not effectively removed by high-flux dialyzers, and effective clearance of large middle molecules in the process of dialysis depends on the dialyzer membrane having large enough pore sizes, larger than the conventional high-flux dialyzers. Studies have found associations between levels of large middle molecule uremic toxins and immune dysfunction and inflammation, as well as adverse outcomes. This indicates that dialysis membranes having larger pores, enabling an expanded HD (HDx) with more effective removal of large middle molecules, can have a positive impact on the inflammatory state. While data is starting to appear on the long-term use of the HDx therapy, little is still known on how large middle molecules and inflammation markers are affected over time.

03

Conditions studied

  • End Stage Renal Disease
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ESRD patients age between 18 - 80 years
  • Clinically stable as judged by the treating physician for 30 days prior to enrollment, as demonstrated by pertinent patient medical history, physical examination, and laboratory testing
  • Hemodialysis therapy with HDF for at least 3 months immediately prior to study enrollment

Exclusion criteria

Exclusion Criteria:

  • No provided
  • Significant psychiatric disorder, mental disability, or other condition that may interfere with the patient's ability to provide informed consent
  • Pregnant, breastfeeding, or planning to become pregnant
  • Unstable vascular access associated with risk of low and variable extracorporeal blood flow rate (QB)
  • Chronic liver disease, known paraprotein-associated disease, known bleeding disorders (e.g., gastrointestinal bleed, colonic polyps, small bowel angiodysplasia and active peptic ulcers)
  • Major bleeding episode (i.e. soft tissue bleeding, blood in stool, joint damage, retinal bleeding, extensive mucosal bleeding, exsanguination, cerebral hemorrhage) ≤ 12 weeks prior to enrollment
  • Blood (red blood cell) transfusion ≤ 12 weeks prior to enrollment
  • Clinical signs of acute infection ≤ 4 weeks prior to enrollment
  • Active cancer, except for basal cell or squamous cell skin cancer
  • Positive serology test for or hepatitis infection
  • Scheduled for planned interventions requiring hospitalization > 1 week
  • Scheduled for living-donor transplantation within the study period
  • Currently participating in another interventional clinical study or has participated in another interventional clinical study in the past 3 months that may interfere with this study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Expanded Hemodialysis (HDx) Therapy

    Patients will undergo 3 dialysis sessions per week with Theranova 500 for up to 24 weeks.

    Device: Theranova 500 medium cut-off dialyzer

  • Active comparator
    Hemodiafiltration (HDF) Therapy

    Patients will undergo 3 dialysis sessions per week with on-line HDF for up to 24 weeks.

    Device: Hemodiafiltration

Interventions

  • DeviceTheranova 500 medium cut-off dialyzer

    The patients randomized in this group using the Theranova 500 medium cut-off dialyzer, and blood flow rate and treatment duration will be maintained stable during the observation period. However, other prescriptions will vary based on the Principal Investigator's (PI's) judgment. If other dialyzers need to be temporarily used during the study period it shall be recorded which alternative dialyzers are used and for how long the study patient is on a different dialyzer. However, prior to Week 12 laboratory assessment it is recommended that the patient undergoes three dialysis sessions on the designated treatment mode.

  • DeviceHemodiafiltration

    The patients randomized in this group using the on-line high-flux HDF dialyzer, in post dilution mode, will continue to receive treatments according to their current treatment prescriptions for the duration of the study.

06

What researchers measure

Primary outcomes

  1. Reduction ratios of lambda immunoglobulin free light chains (λ-FLC)

    Time frame: Week 12

  2. Reduction ratios of kappa immunoglobulin free light chains (k-FLC)

    Time frame: Week 12

  3. Reduction ratios of chitinase-3-like protein 1 (YKL-40)

    Time frame: Week 12

  4. Reduction ratios of fibroblast growth factor 23 (FGF-23)

    Time frame: Week 12

  5. Reduction ratios of serum beta-2 microglobulin (β2M)

    Time frame: Week 12

Secondary outcomes

  1. Change from baseline in mid-week pre-dialysis serum levels of λ-FLC, κ-FLC, YKL-40, FGF-23, ß2M

    Time frame: Week 12 and 24

  2. Change from baseline in mid-week pre-dialysis serum levels of pentraxin-3 (PTX-3), high sensitivity C-reactive protein (hs-CRP), interleukin (IL-6), and interleukin-10 (IL-10)

    Time frame: Week 12 and 24

  3. Percent change from pre- to post-dialysis in mid-week serum levels of hs-CRP

    Time frame: Week 12

  4. Percent change from pre- to post-dialysis in mid-week serum levels of PTX-3

    Time frame: Week 12

  5. Percent change from pre- to post-dialysis in mid-week serum levels of IL-6

    Time frame: Week 12

  6. Percent change from pre- to post-dialysis in mid-week serum levels of IL-10

    Time frame: Week 12

  7. Change from baseline in mid-week pre-dialysis serum level of fibrinogen

    Time frame: Week 12 and 24

  8. Change from baseline in mid-week pre-dialysis serum level of albumin

    Time frame: Week 12 and 24

  9. Single pool Kt/Vurea

    Time frame: Week 24

  10. Serum phosphorous

    Time frame: Week 24

  11. Kidney Disease Quality of Life 36 (KDQOL-36)

    Time frame: Baseline, Week 12, Week 24

  12. Dialysis Symptom Index (DSI)

    Time frame: Baseline, Week 12, Week 24

  13. Serum ferritin

    Time frame: Baseline, Week 12, Week 24

  14. Transferrin Saturation (TSAT)

    Time frame: Baseline, Week 12, Week 24

  15. 24-hour urine output on monthly basis

    Time frame: Month 1, Month 2, Month 3, Month 4, Month 5, Month 6

  16. Erythropoiesis stimulating agent (ESA) responsiveness

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24

  17. Hemoglobin levels

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24

  18. ESA dosage by type, administration frequency, and route

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24

  19. Intravenous iron dosage

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24

  20. Number of adverse events of hospitalization, cardiovascular events, and infective episodes

    Time frame: Week 1 through Week 24

  21. Total patient death

    Time frame: Week 1 through Week 24

07

Study locations

1 site
  • RTS Murcia VII, RTS Servicios de Diálisis S.L.U.
    Murcia, Spain
08

References and documents

Publications

  • Hadad-Arrascue F, Nilsson LG, Rivera AS, Bernardo AA, Cabezuelo Romero JB. Expanded hemodialysis as effective alternative to on-line hemodiafiltration: A randomized mid-term clinical trial. Ther Apher Dial. 2022 Feb;26(1):37-44. doi: 10.1111/1744-9987.13700. Epub 2021 Jun 29. PubMed 34125503 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Oct 2018, 5 months.

Of 78 industry-sponsored interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 40. This study's 5 months is below that.

Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2018
First posted
Apr 17, 2018
StartActual
Apr 11, 2018
Primary completionActual
Oct 4, 2018
CompletionActual
Oct 4, 2018
Last update
Mar 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03499691
Lead sponsor
Vantive Health LLC
Responsible party
Sponsor
First posted
Apr 17, 2018
Start date
Apr 11, 2018
Primary completion
Oct 4, 2018
Completion
Oct 4, 2018
Last update
Mar 13, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion